In 2021, the operating revenue of kangxinuo was about 4.3 billion yuan, with a year-on-year increase of 17174.82% From Kangxinuo financial report

The following is the In 2021, the operating revenue of kangxinuo was about 4.3 billion yuan, with a year-on-year increase of 17174.82% From Kangxinuo financial report recommended by recordtrend.com. And this article belongs to the classification: Enterprise financial report, novel coronavirus.

Recently, consino released its 2021 performance report. According to the data, in 2021, kangxinuo achieved an operating revenue of about 4.3 billion yuan, a year-on-year increase of 17174.82%. The net profit attributable to the shareholders of the listed company was 1.914 billion yuan. After excluding non recurring profits and losses, the net profit attributable to the shareholders of the listed company was about 1.8 billion yuan, which was successfully reversed.

Due to the first profit, kangxinuo became the first biotechnology company to successfully “pick u” on Kechuang board. However, such a brilliant financial report can not boost the company’s share price. After the release of the financial report, kangxinuo’s share price fell for several trading days. Before that, kangxinuo’s share price fell all the way from the high of 798 yuan on June 23 last year. As of April 1, 2022, it closed at 236 yuan, and the market value evaporated nearly 100 billion yuan.

Is the bonus of the new crown vaccine gone?

In February 25, 2021, the State Administration of drugs approved the application of the recombinant New Coronavirus vaccine (trade name: Kwisa). The vaccine became the fourth domestic coronavirus vaccine approved for marketing in China and the first approved adenovirus vector coronavirus vaccine.

Keweisha’s listing coincides with the wave of centralized vaccination of new vaccines in China. In the second quarter of 2021, kangxinuo’s revenue was 1.595 billion yuan, while in the first quarter, the company’s revenue was only 467 million yuan. However, with the listing of new crown vaccines at home and abroad, kangxinuo’s revenue began to decline in the third and fourth quarters, with 1.024 billion yuan and 1.214 billion yuan respectively.

In September 2021, kangxinuo issued the incentive plan for restricted stocks in 2021, and the minimum assessment index set was “revenue of 6 billion yuan in 2021”. However, according to the latest financial report, kangxinuo’s revenue is far lower than expected.

As the new crown vaccine vaccination at home and abroad is coming to an end, the dividend period of the vaccine is disappearing. According to who data, by the end of March 2022, more than 11 billion doses of covid-19 had been vaccinated worldwide, with a vaccine coverage rate of 64%. In China, by the end of February this year, China had completed 3.011 billion doses of Xinguan vaccine, with a total vaccination population of more than 1.26 billion and a vaccine coverage rate of nearly 90%.

After vaccination, Xinguan oral liquid comes again. In February of this year, the State Food and Drug Administration approved the import registration of Pfizer Inc COVID-19 therapeutics NAT Matt Wei / Ritonavir Tablets composite packaging (Paxlovid). On March 17, the first batch of 21200 boxes of paxlovid officially entered China and were distributed to many provinces, which will have a further impact on the demand for the new coronavirus vaccine.

Performance stability to be tested

Although with a new coronavirus vaccine, kangxinuo successfully reversed its losses. But it also exposed the single side of the company’s income structure. Kangxinuo naturally knows its shortcomings and tries to reverse this situation, but most of the company’s products are still in the early stage of R & D or listing.

Up to now, Conchino has approved 3 vaccine products in China, namely, recombinant New Coronavirus vaccine Ad5-nCoV (5 adenovirus vector, MCV2), two valent meningococcal polysaccharide conjugate vaccine MCV2, and tetravalent meningitis combined vaccine MCV4, which were listed in February, June and December respectively.

In addition, novel coronavirus pneumonia is also increasing its layout, and its research and development products cover 17 innovative vaccine products, including Ebola virus disease, meningitis, new crown pneumonia, pneumonia, DPT, tuberculosis and herpes zoster.

Expanding the layout of R & D pipeline means that more capital investment is needed. We should know that vaccine R & D is a very “money burning” activity. According to the statistics of foreign research institutions, the total R & D cost of a vaccine project is about US $1 billion on average, which takes an average of 8-10 years or more.

In kangxinuo’s financial report, R & D investment has also become a large expenditure of the company. In 2020, the R & D investment of the company was 429 million yuan, and in 2021, the R & D investment of the company was 905 million yuan. In the same period, the R & D investment accounted for 21.05% of the operating revenue.

When the epidemic dividend subsides, the driving effect of Xinguan vaccine on the company’s performance is declining. On the other hand, it is necessary to maintain a high amount of R & D investment for future development. Therefore, kangxinuo’s short-term performance soared, but it is not solid.

Perhaps seeing this, major institutional investors have reduced their holdings of kangxinuo. In February 2022, Shanghai Li’an, Suzhou li’tai, LAV spring, LAV bio, Lilly Asia and LAV amber announced the reduction of about 7.94 million a shares and H shares of kangxinuo.

Earlier, on June 21, 2021, JPMorgan sold 7.7 million kangxinuo shares at an average price of HK $374.95 per share, and the shareholding ratio decreased from 9.25% to 3.41%. SDIC advanced manufacturing industry investment fund, the sixth largest shareholder, also began to reduce its holdings of kangxinuo last year, and its original shares of 3.58% have been reduced to the current 2.35%.

Observing more reading from Dahua: CDC: Massachusetts infection 74% is the infection insurance agency that breaks through the vaccine barrier: our country has been vaccinated with 3 billion 200 million doses of more than 1200 yuan, and the cost is shared by the medical insurance fund and the Finance: ILO: COVID-19 has led to 10% reduction in global labor income. “New England Journal of medicine” Novel coronavirus pneumonia can be reduced by novel coronavirus pneumonia: the risk of Omicron hospitalization for children aged 5 to 11 is reduced by 68%WHO: the Global Fund for coping with new crown pneumonia is 3.5 times more than that of the financial crisis. The Secretary General of the United Nations: as of mid July, COVID-19 affected more than 1 billion students WHO: last week, half of the world’s confirmed cases of new crown lung infection were from India, COVID-19, and heavy air strikes on aircraft industry. The delivery of the aircraft dropped sharply. The United Nations: COVID-19 will lead to the first global index of wealth. Slide IDC: COVID-19’s impact on the global IT market is expected to reduce the expenditure in the IT field Quartz: COVID-19 isolation leads to a decline in the use of music streaming media: WHO: the US is about to become the center of COVID-19’s global pop: UNWTO: COVID-19 will make the global tourism industry retrogressive for 20 years IATA: 25 million related jobs in the world are affected by COVID-19, and the 40% population of the earth is segregated at home.

If you want to get the full report, you can contact us by leaving us the comment. If you think the information here might be helpful to others, please actively share it. If you want others to see your attitude towards this report, please actively comment and discuss it. Please stay tuned to us, we will keep updating as much as possible to record future development trends.

RecordTrend.com is a website that focuses on future technologies, markets and user trends. We are responsible for collecting the latest research data, authority data, industry research and analysis reports. We are committed to becoming a data and report sharing platform for professionals and decision makers. We look forward to working with you to record the development trends of today’s economy, technology, industrial chain and business model.Welcome to follow, comment and bookmark us, and hope to share the future with you, and look forward to your success with our help.